Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content

01 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302759783.html

30 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-to-initiate-new-drug-application-submission-from-the-darovasertib-optimum-02-trial-under-the-oncology-center-of-excellence-real-time-oncology-review-rtor-program-302758376.html

21 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-meta-302747826.html

13 Apr 2026
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/ideaya-eye-cancer-drug-meets-main-goal-mid-to-late-stage-trial-2026-04-13/

13 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a0201-negative-metastatic-uveal-melanoma-302739905.html

13 Apr 2026
// BIOSPACE
https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE